Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186637 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Alpine Immune Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT04186637: Clinical Trial Phase 1 study, sponsored by Alpine Immune Sciences.
NCT04186637 is a Phase 1 study that was terminated before completion, run by Alpine Immune Sciences. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04186637, a Phase 1 study, was terminated before completion, sponsored by Alpine Immune Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
Primary Outcome
Type, incidence, and severity of adverse events as assessed by CTCAE
Interventions
- DRUG ALPN-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Why NCT04186637 stopped before completion
NCT04186637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ALPN-202 is the first listed.
NCT04186637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04186637 about?
NCT04186637 is a clinical study titled "An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies". This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
What is the current status of trial NCT04186637?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2020-06-02. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04186637?
The interventions under investigation include: ALPN-202 (DRUG).
Who is sponsoring clinical trial NCT04186637?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04186637's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI